Roche Diagnostics Foresees Revenue Increase From DNA Microarray Area
This article was originally published in PharmAsia News
At a briefing in Tokyo, Roche Diagnostics Japan President Wataru Ogawa said he foresees a revenue of ¥4.1 billion ($38.2 million), a 24 percent increase in its Applied Science business. He said ¥0.5 billion ($4.63 million) will come from new entrants such as DNA microarrays. Ogawa also anticipates a strong demand for point-of-care testing devices in time for a new health guidance that takes effect in April. Roche Diagnostics plans on launching 12 new products in 2008, including high sensitivity DNA microarrays and real-time cell analysis systems. (Click for more-Japanese language
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.